Cellid Crashes After-Hours on Phase 3 Failure...Shaperon Dives 25%[K-bio pulse]

[Kim Jinsoo, Edaily Reporter] In the biopharmaceutical sector on Friday, Cellid’s stock surged on expectations for its vaccine clinical trial results, but the shares plunged by the daily limit in after-hours trading following news of a Phase 3 trial failure.

A further decline is expected on the next trading day.

Shaperon also saw a significant drop for two consecutive trading days following its own clinical trial failure, though the company hopes for a turnaround by unveiling strategies to continue its trials.